nmda receptors Search Results


94
Alomone Labs polyclonal rabbit anti glun2d subunit
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Polyclonal Rabbit Anti Glun2d Subunit, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/bio_rxiv__64898__2026__03__06__710109-151-27-31?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
polyclonal rabbit anti glun2d subunit - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

90
OriGene rabbit anti glun2d
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Rabbit Anti Glun2d, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc07005343-406-57-65?v=OriGene
Average 90 stars, based on 1 article reviews
rabbit anti glun2d - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

85
Rockland Immunochemicals rabbit anti py1336 glun2b antibody
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Rabbit Anti Py1336 Glun2b Antibody, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc04126770-62-5-9?v=Rockland+Immunochemicals
Average 85 stars, based on 1 article reviews
rabbit anti py1336 glun2b antibody - by Bioz Stars, 2026-08
85/100 stars
  Buy from Supplier

86
Rockland Immunochemicals rabbit anti glun2a
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Rabbit Anti Glun2a, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc05323044-518-157-161?v=Rockland+Immunochemicals
Average 86 stars, based on 1 article reviews
rabbit anti glun2a - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier

94
Alomone Labs alomone labs agc
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Alomone Labs Agc, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/bio_rxiv__64898__2026__04__13__718261-268-15-15?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
alomone labs agc - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
Alomone Labs agc001
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Agc001, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc12981561-9-4-2?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
agc001 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
OriGene plasmids
(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with <t>an</t> <t>anti-GluN2D</t> antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.
Plasmids, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pm41005304-332-7-19?v=OriGene
Average 93 stars, based on 1 article reviews
plasmids - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

90
Addgene inc nmda receptors plasmids
a Cartoon illustrating the <t>NMDA</t> subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from <t>the</t> <t>NR2A</t> purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.
Nmda Receptors Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc07665045-248-0-6?v=Addgene+inc
Average 90 stars, based on 1 article reviews
nmda receptors plasmids - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

95
Alomone Labs polyclonal antibody against nr2b
a Cartoon illustrating the <t>NMDA</t> subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from <t>the</t> <t>NR2A</t> purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.
Polyclonal Antibody Against Nr2b, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc02575496-245-17-23?v=Alomone+Labs
Average 95 stars, based on 1 article reviews
polyclonal antibody against nr2b - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

90
Alomone Labs anti nr2b
a Cartoon illustrating the <t>NMDA</t> subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from <t>the</t> <t>NR2A</t> purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.
Anti Nr2b, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc03658443-84-4-5?v=Alomone+Labs
Average 90 stars, based on 1 article reviews
anti nr2b - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

94
Alomone Labs rabbit anti glun2a
a Cartoon illustrating the <t>NMDA</t> subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from <t>the</t> <t>NR2A</t> purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.
Rabbit Anti Glun2a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc04469732-132-15-12?v=Alomone+Labs
Average 94 stars, based on 1 article reviews
rabbit anti glun2a - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
Alomone Labs anti glun1 nmdar subunit
The D1R–NMDAR interaction bidirectionally regulates the surface distribution and dynamics of D1R and NMDAR. (A) Immunostaining of surface D1R-CFP (green) and <t>GluN1</t> subunit (red) in hippocampal neurons. The yellow arrow shows overlay. (B) Immunostaining of surface D1R-CFP in control or after D1/5R agonist, TAT-t2, or TAT-[N2A15] application. (Scale bar, 250 nm.) (C) Normalized measures of D1R-CFP clusters intensity in control (n = 32 neuronal fields), D1/5R agonist-treated (n = 24 neuronal fields; *P < 0.05 compared with control), TAT-NSt2–treated (non-sense of TAT-t2, n = 19 neuronal fields), TAT-t2–treated (n = 21 neuronal fields; **P < 0.01 compared with TAT-NSt2), TAT-NSt3–treated (non-sense of TAT-t3, n = 11 neuronal fields), TAT-t3–treated (n = 12 neuronal fields; P > 0.05 compared with TAT-NSt3), TAT-[NS15]–treated (n = 27 neuronal fields; P > 0.05), or TAT-[N2A15]–treated (n = 21 neuronal fields, *P < 0.05 compared with TAT-[NS15]) conditions. (D) Representative trajectories (1,000 frames, 20-Hz acquisition rate) of surface single D1R-CFP (Left) (green) (scale bar, 400 nm) and GluN1-NMDAR (Right) (blue) (scale bar, 300 nm) in the absence and presence of either D1/5R agonist (10 µM, 15 min) or TAT-t2 (10 µM, 15 min). Bold dotted line, perisynaptic area; thin dotted line, PSD area. (E) Plot of the MSD of surface D1R-CFP (Upper) (green) and GluN1-NMDAR (Lower) (blue) versus time in presence of TAT-NS or TAT-t2 peptides (10 µM, 15 min). The SEM is included for each data point (D1R: TAT-NS, n = 986 trajectories, and TAT-t2, n = 1,326; GluN1-NMDAR: TAT-NS, n = 198, and TAT-t2, n = 134). (F and G) Representative surface distributions of single D1R-CFP (green) (F) and GluN1-NMDAR (blue) (G) in the synaptic area (PSD + perisynaptic area) in control, D1/5R agonist, and TAT-t2 conditions. Each dot represents the detection of a single receptor during a frame. Comparisons of the time spent in the synaptic area (dwell time) by single D1R-CFP (control, n = 173 trajectories; D1/5R agonist, n = 142, **P < 0.01; TAT-t2, n = 752, *P < 0.05) (F) and GluN1-NMDAR (control, n = 189 trajectories; D1/5R agonist, n = 157, *P < 0.05; TAT-t2, n = 134, **P < 0.01) (G) and the synaptic fraction of detected single D1R-CFP (control, n = 14 neuronal fields; D1/5R agonist, n = 19, **P < 0.01; D1/5R agonist in the presence of dynasore, n = 47, **P < 0.01; TAT-t2, n = 15, ***P < 0.001) (F), D5R-CFP (n = 16, P > 0.05) (F), and GluN1-NMDAR (control, n = 11; D1/5R agonist, n = 15, *P < 0.05; TAT-t2, n = 14, *P < 0.05) (G). Dyn., dynasore; D1/5 ago., D1/5 receptor agonist SKF-38393.
Anti Glun1 Nmdar Subunit, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nmda+receptors/pmc03816474-241-53-57?v=Alomone+Labs
Average 93 stars, based on 1 article reviews
anti glun1 nmdar subunit - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


(A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with an anti-GluN2D antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.

Journal: bioRxiv

Article Title: GluN2D-containing NMDA receptors regulate dentate gyrus function by facilitating granule cell activity and mediating synaptic plasticity

doi: 10.64898/2026.03.06.710109

Figure Lengend Snippet: (A) Grin2d f l/fl mice were injected with AAV5-CamKII-mCherry (Control) or AAV-CamKII-mCherry-Cre ( Grin2d cKO). NMDAR-LTP was abolished in Grin2d cKO compared with control mice (Control: 149.5 ± 6.0 %, p < 0.01, n = 5, paired t-test; cKO: 92.5 ± 5.3 %, p = 0.12201, n = 6, paired t-test; Control vs cKO: p < 0.001, unpaired t-test). (B) WT mice were bilaterally injected with an anti-GluN2D antibody or control Ab into the dentate gyrus. After one hour, animals were euthanized, and slices were prepared. Injection was confirmed by the presence of methylene blue. NMDAR-LTP was abolished in mice injected with the anti-GluN2D antibody (cKO: 110.4 ± 8.5 %, p = 0.2952, n = 6, paired t-test) compared with control mice (Control: 149.8 ± 8.1 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.01, unpaired t-test). (C) NMDAR-LTP was impaired in Grid1 KO mice (KO: 117.7 ± 5.3, p < 0.05%, n = 8, Wilcoxon signed-rank test) compared with controls (Control: 147.5 ± 6.7 %, p < 0.001, n = 7, paired t-test; Control vs cKO: p < 0.05, Mann-Whitney U test). Data are presented as mean ± s.e.m.

Article Snippet: For GluN2D cross-linking experiments in C57BL/6J, the control group received 1 μL of anti-rabbit Alexa 568 (control IgG, 1/5), while the GluN2D-cross-link group received 1 μg of polyclonal rabbit anti-GluN2D subunit (Alomone Labs, cat #AGC-020), both diluted in PBS with 1% methylene blue (1 μL final volume).

Techniques: Injection, Control, MANN-WHITNEY

a Cartoon illustrating the NMDA subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.

Journal: Communications Biology

Article Title: Phosphorylation of NMDA receptors by cyclin B/CDK1 modulates calcium dynamics and mitosis

doi: 10.1038/s42003-020-01393-3

Figure Lengend Snippet: a Cartoon illustrating the NMDA subunit combinations purified from cells in interphase. The cylinders represent the subunits of the NMDAR. The triangles simulate the phosphorus given by the cyclin B1/CDK1 complex (green circle/yellow square). The subunits with the alanine mutant (mA) are not phosphorylated by the complex. c , d Purified NR1wt/NR2Awt, NR1mA/NR2Awt and NR1wt/NR2AmA were incubated with a purified recombinant CyclinB1/CDK1 complex (see “Materials and methods” section) for an in vitro phosphorylation assay. b Blots using the MPM2 antibody. NR1wt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas of NR1wt from combination NR1wt/NR2mA. NR1mA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. NR2Awt blot shows in lanes 1–2 replicas of NR1wt from the combination NR1wt/NR2Awt; and lanes 3–4 replicas from the NR2A purified from the combination NR1mA/NR2Awt. Finally, NR2AmA blot shows in lanes 1–4 replicas from the NR2A purified from the combination NR1wt/NR2AmA. c Blots show in the same order the total protein content identified by Coomassie staining. d Blots show the total protein (left) and western blot using the MPM2 antibody (right) from the combination NR1wt/NR2Awt which was not incubated with the phosphorylation cocktail containing the recombinant purified Cyclin B1/CDK1 complex. Lanes 1–2 replicas from NR1wt and lanes 3–4 replicas from NR2Awt. This was used to assess the background phosphorylation of NMDAR purified from cells in interphase.

Article Snippet: NMDA receptors plasmids were acquired from Addgene: pCI-EGFP-NR1 wt (#45446) and pCI-SEP_NR2A (#23997).

Techniques: Purification, Mutagenesis, Incubation, Recombinant, In Vitro, Phospho-proteomics, Staining, Western Blot

The D1R–NMDAR interaction bidirectionally regulates the surface distribution and dynamics of D1R and NMDAR. (A) Immunostaining of surface D1R-CFP (green) and GluN1 subunit (red) in hippocampal neurons. The yellow arrow shows overlay. (B) Immunostaining of surface D1R-CFP in control or after D1/5R agonist, TAT-t2, or TAT-[N2A15] application. (Scale bar, 250 nm.) (C) Normalized measures of D1R-CFP clusters intensity in control (n = 32 neuronal fields), D1/5R agonist-treated (n = 24 neuronal fields; *P < 0.05 compared with control), TAT-NSt2–treated (non-sense of TAT-t2, n = 19 neuronal fields), TAT-t2–treated (n = 21 neuronal fields; **P < 0.01 compared with TAT-NSt2), TAT-NSt3–treated (non-sense of TAT-t3, n = 11 neuronal fields), TAT-t3–treated (n = 12 neuronal fields; P > 0.05 compared with TAT-NSt3), TAT-[NS15]–treated (n = 27 neuronal fields; P > 0.05), or TAT-[N2A15]–treated (n = 21 neuronal fields, *P < 0.05 compared with TAT-[NS15]) conditions. (D) Representative trajectories (1,000 frames, 20-Hz acquisition rate) of surface single D1R-CFP (Left) (green) (scale bar, 400 nm) and GluN1-NMDAR (Right) (blue) (scale bar, 300 nm) in the absence and presence of either D1/5R agonist (10 µM, 15 min) or TAT-t2 (10 µM, 15 min). Bold dotted line, perisynaptic area; thin dotted line, PSD area. (E) Plot of the MSD of surface D1R-CFP (Upper) (green) and GluN1-NMDAR (Lower) (blue) versus time in presence of TAT-NS or TAT-t2 peptides (10 µM, 15 min). The SEM is included for each data point (D1R: TAT-NS, n = 986 trajectories, and TAT-t2, n = 1,326; GluN1-NMDAR: TAT-NS, n = 198, and TAT-t2, n = 134). (F and G) Representative surface distributions of single D1R-CFP (green) (F) and GluN1-NMDAR (blue) (G) in the synaptic area (PSD + perisynaptic area) in control, D1/5R agonist, and TAT-t2 conditions. Each dot represents the detection of a single receptor during a frame. Comparisons of the time spent in the synaptic area (dwell time) by single D1R-CFP (control, n = 173 trajectories; D1/5R agonist, n = 142, **P < 0.01; TAT-t2, n = 752, *P < 0.05) (F) and GluN1-NMDAR (control, n = 189 trajectories; D1/5R agonist, n = 157, *P < 0.05; TAT-t2, n = 134, **P < 0.01) (G) and the synaptic fraction of detected single D1R-CFP (control, n = 14 neuronal fields; D1/5R agonist, n = 19, **P < 0.01; D1/5R agonist in the presence of dynasore, n = 47, **P < 0.01; TAT-t2, n = 15, ***P < 0.001) (F), D5R-CFP (n = 16, P > 0.05) (F), and GluN1-NMDAR (control, n = 11; D1/5R agonist, n = 15, *P < 0.05; TAT-t2, n = 14, *P < 0.05) (G). Dyn., dynasore; D1/5 ago., D1/5 receptor agonist SKF-38393.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors

doi: 10.1073/pnas.1310145110

Figure Lengend Snippet: The D1R–NMDAR interaction bidirectionally regulates the surface distribution and dynamics of D1R and NMDAR. (A) Immunostaining of surface D1R-CFP (green) and GluN1 subunit (red) in hippocampal neurons. The yellow arrow shows overlay. (B) Immunostaining of surface D1R-CFP in control or after D1/5R agonist, TAT-t2, or TAT-[N2A15] application. (Scale bar, 250 nm.) (C) Normalized measures of D1R-CFP clusters intensity in control (n = 32 neuronal fields), D1/5R agonist-treated (n = 24 neuronal fields; *P < 0.05 compared with control), TAT-NSt2–treated (non-sense of TAT-t2, n = 19 neuronal fields), TAT-t2–treated (n = 21 neuronal fields; **P < 0.01 compared with TAT-NSt2), TAT-NSt3–treated (non-sense of TAT-t3, n = 11 neuronal fields), TAT-t3–treated (n = 12 neuronal fields; P > 0.05 compared with TAT-NSt3), TAT-[NS15]–treated (n = 27 neuronal fields; P > 0.05), or TAT-[N2A15]–treated (n = 21 neuronal fields, *P < 0.05 compared with TAT-[NS15]) conditions. (D) Representative trajectories (1,000 frames, 20-Hz acquisition rate) of surface single D1R-CFP (Left) (green) (scale bar, 400 nm) and GluN1-NMDAR (Right) (blue) (scale bar, 300 nm) in the absence and presence of either D1/5R agonist (10 µM, 15 min) or TAT-t2 (10 µM, 15 min). Bold dotted line, perisynaptic area; thin dotted line, PSD area. (E) Plot of the MSD of surface D1R-CFP (Upper) (green) and GluN1-NMDAR (Lower) (blue) versus time in presence of TAT-NS or TAT-t2 peptides (10 µM, 15 min). The SEM is included for each data point (D1R: TAT-NS, n = 986 trajectories, and TAT-t2, n = 1,326; GluN1-NMDAR: TAT-NS, n = 198, and TAT-t2, n = 134). (F and G) Representative surface distributions of single D1R-CFP (green) (F) and GluN1-NMDAR (blue) (G) in the synaptic area (PSD + perisynaptic area) in control, D1/5R agonist, and TAT-t2 conditions. Each dot represents the detection of a single receptor during a frame. Comparisons of the time spent in the synaptic area (dwell time) by single D1R-CFP (control, n = 173 trajectories; D1/5R agonist, n = 142, **P < 0.01; TAT-t2, n = 752, *P < 0.05) (F) and GluN1-NMDAR (control, n = 189 trajectories; D1/5R agonist, n = 157, *P < 0.05; TAT-t2, n = 134, **P < 0.01) (G) and the synaptic fraction of detected single D1R-CFP (control, n = 14 neuronal fields; D1/5R agonist, n = 19, **P < 0.01; D1/5R agonist in the presence of dynasore, n = 47, **P < 0.01; TAT-t2, n = 15, ***P < 0.001) (F), D5R-CFP (n = 16, P > 0.05) (F), and GluN1-NMDAR (control, n = 11; D1/5R agonist, n = 15, *P < 0.05; TAT-t2, n = 14, *P < 0.05) (G). Dyn., dynasore; D1/5 ago., D1/5 receptor agonist SKF-38393.

Article Snippet: For single-nanoparticle tracking, QD 655 coupled to goat anti-rabbit F(ab′) 2 or anti-mouse IgG (Invitrogen) was incubated (1:10,000, 10 min) onto neurons previously exposed for 10 min to either mouse monoclonal anti-GFP (1 µg; Invitrogen), rabbit polyclonal anti-D1R (1 µg; Lifespan Biosciences), mouse monoclonal anti-GluA2:00 AMPAR subunit (1 µg; Millipore), or rabbit polyclonal anti–GluN1-NMDAR subunit (1 µg; Alomone Laboratories) antibodies.

Techniques: Immunostaining

D1R activation or D1R/GluN1-NMDAR interaction blockade increases synaptic NMDAR content and favors AMPAR synaptic long-term potentiation. (A) (Left) Excitatory postsynaptic current traces recorded at −70 mV and +40 mV from a representative hippocampal CA1 pyramidal cell, before and 10 min after exposure to D1/5R agonist. (Right) Relative change over time of the AMPA/NMDA ratio at CA1 synapses in the absence or presence of D1/5R agonist (n = 13, *P < 0.05 10 min after agonist) and in the absence or presence of vehicle (n = 7, P > 0.05). (B) Surface imaging of GluN1-SEP in neurons incubated with either TAT-NS or TAT-t2 (10 µM). (Scale bar, 5 µm.) (Right) Average value of GluN1-SEP content in the synaptic area after TAT-NS or TAT-t2 application (n = 8 neurons per group, **P < 0.01). (C) Dendritic fragment of a hippocampal neuron expressing Homer 1c-DsRed (Upper) and GluA1-SEP (Lower). SEP only fluoresces at neutral pH when receptors are inserted at the plasma membrane. Ten minutes after chemical LTP induction (cLTP), the GluA1-SEP fluorescence intensity increased in postsynaptic clusters. (Insets) High magnification of a synaptic GluA1-SEP cluster. (Scale bar, 2 µm.) (D) Comparison of the synaptic GluA1-SEP fluorescence intensity before and after cLTP with prior TAT-NS (n = 198 synapses, *P < 0.05) or TAT-t2 (n = 215 synapses, *P < 0.05) (TAT-NS versus TAT-t2; *P < 0.05) application. (E) Schematic model of the D1R–NMDAR surface interplay in hippocampal neurons. D1Rs are highly diffusive at the neuronal surface and are dynamically retained in clusters in the vicinity of glutamate synapses where they interact with NMDAR. Dopamine release disrupts this interaction and favors the lateral redistribution of both receptors: D1Rs freely explore extrasynaptic areas, whereas NMDARs laterally reach the PSD where they impact on the long-term plasticity of glutamate synapses.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: Single-molecule imaging of the functional crosstalk between surface NMDA and dopamine D1 receptors

doi: 10.1073/pnas.1310145110

Figure Lengend Snippet: D1R activation or D1R/GluN1-NMDAR interaction blockade increases synaptic NMDAR content and favors AMPAR synaptic long-term potentiation. (A) (Left) Excitatory postsynaptic current traces recorded at −70 mV and +40 mV from a representative hippocampal CA1 pyramidal cell, before and 10 min after exposure to D1/5R agonist. (Right) Relative change over time of the AMPA/NMDA ratio at CA1 synapses in the absence or presence of D1/5R agonist (n = 13, *P < 0.05 10 min after agonist) and in the absence or presence of vehicle (n = 7, P > 0.05). (B) Surface imaging of GluN1-SEP in neurons incubated with either TAT-NS or TAT-t2 (10 µM). (Scale bar, 5 µm.) (Right) Average value of GluN1-SEP content in the synaptic area after TAT-NS or TAT-t2 application (n = 8 neurons per group, **P < 0.01). (C) Dendritic fragment of a hippocampal neuron expressing Homer 1c-DsRed (Upper) and GluA1-SEP (Lower). SEP only fluoresces at neutral pH when receptors are inserted at the plasma membrane. Ten minutes after chemical LTP induction (cLTP), the GluA1-SEP fluorescence intensity increased in postsynaptic clusters. (Insets) High magnification of a synaptic GluA1-SEP cluster. (Scale bar, 2 µm.) (D) Comparison of the synaptic GluA1-SEP fluorescence intensity before and after cLTP with prior TAT-NS (n = 198 synapses, *P < 0.05) or TAT-t2 (n = 215 synapses, *P < 0.05) (TAT-NS versus TAT-t2; *P < 0.05) application. (E) Schematic model of the D1R–NMDAR surface interplay in hippocampal neurons. D1Rs are highly diffusive at the neuronal surface and are dynamically retained in clusters in the vicinity of glutamate synapses where they interact with NMDAR. Dopamine release disrupts this interaction and favors the lateral redistribution of both receptors: D1Rs freely explore extrasynaptic areas, whereas NMDARs laterally reach the PSD where they impact on the long-term plasticity of glutamate synapses.

Article Snippet: For single-nanoparticle tracking, QD 655 coupled to goat anti-rabbit F(ab′) 2 or anti-mouse IgG (Invitrogen) was incubated (1:10,000, 10 min) onto neurons previously exposed for 10 min to either mouse monoclonal anti-GFP (1 µg; Invitrogen), rabbit polyclonal anti-D1R (1 µg; Lifespan Biosciences), mouse monoclonal anti-GluA2:00 AMPAR subunit (1 µg; Millipore), or rabbit polyclonal anti–GluN1-NMDAR subunit (1 µg; Alomone Laboratories) antibodies.

Techniques: Activation Assay, Imaging, Incubation, Expressing, Fluorescence